Aspen Neuroscience Cofounder Dr. Andrés Bratt-Leal Receives 2023 Biocom California Life Science Catalyst Award
Dr. Andrés Bratt-Leal, co-founder and Senior Vice President of Research and Development at Aspen Neuroscience, has been honored with the prestigious 2023 Biocom California Life Science Catalyst Award. This accolade, presented by Biocom California, recognizes the most inspiring and driven young minds in the California life sciences industry who are making significant contributions to human […]
FDA Grants Fast Track Designation to ANPD001 for Parkinson’s Disease Treatment
Aspen Neuroscience, a clinical development-stage company, recently announced a significant milestone in the fight against Parkinson’s disease (PD). The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to ANPD001, an autologous (personalized) investigational cell therapy designed to treat Parkinson’s disease by replacing lost dopamine neurons. This designation aims to accelerate the development […]
Rune Labs and Aspen Neuroscience Collaborate on Parkinson’s Disease Study
Rune Labs, a leading precision neurology software and data platform company, has joined forces with Aspen Neuroscience Inc., a prominent autologous cell therapy biotechnology firm. The collaboration aims to leverage Rune Labs’ StriveStudy clinical development platform, enabling Aspen to gather real-time, longitudinal patient data remotely. The primary objective of this partnership is to utilize the […]
Aspen’s Breakthrough FDA-Cleared Parkinson’s Cell Therapy Unveiled
Aspen Neuroscience has announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for ANPD001, an autologous cell therapy designed to treat Parkinson’s Disease (PD) by replacing lost dopamine neurons. The clearance enables Aspen to initiate a first-in-patient Phase 1/2a clinical trial for individuals with moderate to severe […]
Aspen Neuroscience Inks $40 Million Debt Deal with Silicon Valley Bank
SAN DIEGO, Dec. 21, 2022 /PRNewswire/ — Aspen Neuroscience, Inc., a private biotechnology company developing autologous cell therapies including the first iPSC-derived autologous neuron replacement treatment for Parkinson’s disease (PD), has signed a $40 million credit facility with Silicon Valley Bank (SVB). Deal terms were not disclosed. “We are pleased to work with Silicon Valley Bank. As a leader […]